The proform of eosinophil major basic protein: a new maternal serum marker for adverse pregnancy outcome
Article first published online: 22 JUL 2009
Copyright © 2009 John Wiley & Sons, Ltd.
Volume 29, Issue 11, pages 1013–1019, November 2009
How to Cite
Pihl, K., Larsen, T., Rasmussen, S., Krebs, L. and Christiansen, M. (2009), The proform of eosinophil major basic protein: a new maternal serum marker for adverse pregnancy outcome. Prenat. Diagn., 29: 1013–1019. doi: 10.1002/pd.2331
- Issue published online: 26 OCT 2009
- Article first published online: 22 JUL 2009
- Manuscript Accepted: 13 JUN 2009
- Manuscript Revised: 12 JUN 2009
- Manuscript Received: 16 APR 2009
- serum markers;
- first trimester;
- preterm delivery;
To establish the first trimester serum levels of the proform of eosinophil major basic protein (proMBP) in pregnancies with adverse outcome. Furthermore, to determine the screening performance using proMBP alone and in combination with other first trimester markers.
A case-control study was conducted in a primary hospital setting. The proMBP concentration was measured in cases with small-for-gestational age (SGA) (n = 150), spontaneous preterm delivery (n = 88), preeclampsia (n = 40), gestational hypertension (n = 10) and in controls (n = 500). Concentrations were converted to multiples of the median (MoM) in controls and groups were compared using Mann–Whitney U-test. Logistic regression analysis was used to determine significant factors for predicting adverse pregnancy outcome. Screening performance was assessed using receiver operating characteristic curves.
The proMBP median was significantly reduced in pregnancies with SGA (0.81 MoM), spontaneous preterm delivery (0.83 MoM), preeclampsia (0.88 MoM) and gestational hypertension (0.60 MoM). The best screening performance was found for preeclampsia including the covariates proMBP and nulliparity yielding an area under the curve equal to 0.737 (p < 0.0005) and a 75% detection rate for a 30% false positive rate.
The proMBP is a novel first trimester serum marker for adverse pregnancy outcome. Copyright © 2009 John Wiley & Sons, Ltd.